Panneer-Selvam
N, Alamoudi A, Riley III J, Katz J. Does Drug Holiday Affect Jaw Trabeculation
in Medication Related Osteonecrosis of the Jaw? – A Pilot Study. J Clin Exp
Dent. 2022;14(4):e341-8.
doi:10.4317/jced.59503
https://doi.org/10.4317/jced.59503
___________
References
|
1.
Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, et al.
Osteonecrosis of the Jaw in the United States Food and Drug Administration's
Adverse Event Reporting System (FAERS). J Bone Miner Res. 2016;31:336-40. |
|
|
|
|
|
2.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al.
American Association of Oral and Maxillofacial Surgeons position paper on
medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg.
2014;72:1938-56. |
|
|
|
|
|
3.
Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in
cancer patients receiving denosumab: a meta-analysis of seven randomized
controlled trials. Int J Clin Oncol. 2014;19:403-10. |
|
|
|
|
|
4.
Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, Takahashi K, et al.
Increased incidence of osteonecrosis of the jaw after tooth extraction in
patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac
Surg. 2012;41:1397-403. |
|
|
|
|
|
5.
Scoletta M, Arata V, Arduino PG, Lerda E, Chiecchio A, Gallesio G, et al.
Tooth extractions in intravenous bisphosphonate-treated patients: a refined
protocol. J Oral Maxillofac Surg. 2013;71:994-9. |
|
|
|
|
|
6.
Damm DD, Jones DM. Bisphosphonate-related osteonecrosis of the jaws: a
potential alternative to drug holidays. Gen Dent. 2013;61:33-8. PMid:23928436 |
|
|
|
|
|
7.
Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther
Adv Musculoskelet Dis. 2013;5:107-11. |
|
|
|
|
|
8.
Hasegawa T, Kawakita A, Ueda N, Funahara R, Tachibana A, Kobayashi M, et al.
A multicenter retrospective study of the risk factors associated with
medication-related osteonecrosis of the jaw after tooth extraction in
patients receiving oral bisphosphonate therapy: can primary wound closure and
a drug holiday really prevent MRONJ? Osteoporos Int. 2017;28:2465-73. |
|
|
|
|
|
9.
Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S, et al.
Managing the care of patients receiving antiresorptive therapy for prevention
and treatment of osteoporosis: executive summary of recommendations from the
American Dental Association Council on Scientific Affairs. J Am Dent Assoc.
2011;142:1243-51. |
|
|
|
|
|
10.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al.
Diagnosis and management of osteonecrosis of the jaw: a systematic review and
international consensus. J Bone Miner Res. 2015;30:3-23. |
|
|
|
|
|
11.
Gaalaas L, Henn L, Gaillard P, Ahmad M, Islam M. Analysis of trabecular bone
using site-specific fractal values calculated from cone beam CT images. Oral
Radiol. 2013;30:179-85. |
|
|
|
|
|
12.
Fleisch H. Bisphosphonates in osteoporosis. In: Aebi M, Gunzburg R, Szpalski
M, editors. The Aging Spine. Berlin, Heidelberg: Springer Berlin Heidelberg;
2005. p. 60-4. |
|
|
|
|
|
13.
Papapoulos SE, Cremers SCLM. Prolonged bisphosphonate release after treatment
in children. N Engl J Med. 2007;356:1075-6. |
|
|
|
|
|
14.
Tofé VI, Bagán L, Bagán J V. Osteonecrosis of the jaws associated with
denosumab: Study of clinical and radiographic characteristics in a series of
clinical cases. J Clin Exp Dent. 2020;12:e676-81. |
|
|
|
|
|
15.
Malan J, Ettinger K, Naumann E, Beirne OR. The relationship of denosumab
pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol
Oral Radiol. 2012;114:671-6. |
|
|
|
|
|
16.
Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, et al.
Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone
resorption and increases BMD in knock-in mice that express chimeric
(murine/human) RANKL. J bone Miner Res Off J Am Soc Bone Miner Res. 2009;24:182-95. |
|
|
|
|
|
17.
Kato CN, Barra SG, Tavares NP, Amaral TM, Brasileiro CB, Mesquita RA, et al.
Use of fractal analysis in dental images: a systematic review. Dentomaxillofac
Radiol. 2020;49:20180457. |
|
|
|
|
|
18.
González-García R, Monje F. The reliability of cone-beam computed tomography
to assess bone density at dental implant recipient sites: a histomorphometric
analysis by micro-CT. Clin Oral Implants Res. 2013;24:871-9. |
|
|
|
|
|
19.
Panmekiate S, Ngonphloy N, Charoenkarn T, Faruangsaeng T, Pauwels R.
Comparison of mandibular bone microarchitecture between micro-CT and CBCT
images. Dentomaxillofac Radiol. 2015;44:20140322. |
|
|
|
|
|
20.
Bollen AM, Taguchi A, Hujoel PP, Hollender LG. Fractal dimension on dental
radiographs. Dentomaxillofac Radiol. 2001;30:270-5. |
|
|
|
|
|
21.
Black DM, Schwartz A V, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al.
Effects of continuing or stopping alendronate after 5 years of treatment: the
Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.
JAMA. 2006;296:2927-38. |
|
|
|
|
|
22.
Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al.
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis:
a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J bone
Miner Res Off J Am Soc Bone Miner Res. 2012;27:243-54. |
|
|
|
|
|
23.
Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al. The
effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a
randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J
bone Miner Res Off J Am Soc Bone Miner Res. 2015;30:934-44. |
|
|
|
|
|
24.
Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, et al.
Fracture risk remains reduced one year after discontinuation of risedronate.
Osteoporos Int a J Establ as result Coop between Eur Found Osteoporos Natl
Osteoporos Found USA. 2008;19:365-72. |
|